Income Statement
RECURSION PHARMACEUTICALS, INC.
RXRX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
74.68 | 58.84 | 44.58 | 39.84 | 10.18 |
|
Cost of Revenue
|
70.95 | 45.24 | 42.59 | 48.28 | - |
|
Gross Profit
|
3.73 | 13.60 | 1.99 | -8.43 | 10.18 |
|
Operating Expenses
|
651.86 | 492.61 | 352.05 | 237.30 | 192.95 |
|
Research & Development
|
475.27 | 314.42 | 241.23 | 155.70 | 135.27 |
|
Selling, General & Administrative
|
176.59 | 178.18 | 110.82 | 81.60 | 57.68 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-648.13 | -479.00 | -350.06 | -245.73 | -182.78 |
|
Non-Operating Income
|
3.24 | 14.22 | 17.93 | 6.25 | -3.70 |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | 0.10 | 0.06 | 2.95 |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-644.90 | -464.79 | -332.13 | - | - |
|
Income Tax Expense
|
-0.14 | -1.13 | -4.06 | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-644.76 | -463.66 | -328.07 | -239.48 | -186.48 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-564.43 | -442.51 | -325.66 | -233.97 | -174.37 |
|
Earnings Per Share (Basic)
|
-1.44 | -1.69 | -1.58 | -1.36 | -1.49 |
|
Diluted EPS
|
-1.44 | -1.69 | -1.58 | -1.36 | -1.49 |
|
Weighted Average Shares
|
447.45 | 274.21 | 207.85 | 175.54 | 125.35 |
|
Diluted Weighted Avg Shares
|
447.45 | 274.21 | 207.85 | 175.54 | 125.35 |
|
Comprehensive Income
|
-600.41 | -471.30 | -328.07 | -239.35 | -186.61 |